Inhibikase Therapeutics, Inc. (IKT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Key ratios (FY2025)
-27.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $260.5K | $123.4K | $3.10M | $698.5K | — |
| Operating Income | -$51.97M | -$28.59M | -$20.09M | -$18.13M | -$14.77M | -$2.82M | — |
| Net Income | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M | -$2.85M | — |
| EPS (Diluted) | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-0.81 | — | — |
| Total Assets | $181.20M | $98.60M | $14.51M | $24.94M | $42.47M | $14.78M | — |
| Total Liabilities | $8.30M | $3.73M | $3.53M | $3.90M | $4.05M | $5.00M | — |
| Shareholders' Equity | $172.90M | $94.87M | $10.98M | $21.04M | $38.42M | $9.78M | -$4.49M |
| Cash & Equivalents | $178.80M | $97.50M | $9.20M | $7.19M | $40.75M | — | — |
| Operating Cash Flow | -$27.79M | -$19.15M | -$18.09M | -$17.35M | -$14.30M | -$1.13M | — |
| Capital Expenditures | $13.4K | $0 | $14.2K | $243.3K | $0 | — | — |
| Shares Outstanding | 131.69M | 69.36M | 6.19M | 4.22M | 25.16M | 10.05M | — |